Cargando…

Clinical considerations in individuals with α(1)-antitrypsin PI*SZ genotype

α(1)-Antitrypsin deficiency (AATD), characterised by reduced levels or functionality of α(1)-antitrypsin (AAT), is a significantly underdiagnosed genetic condition that predisposes individuals to lung and liver disease. Most of the available data on AATD are based on the most common, severe deficien...

Descripción completa

Detalles Bibliográficos
Autores principales:	McElvaney, Gerard N., Sandhaus, Robert A., Miravitlles, Marc, Turino, Gerard M., Seersholm, Niels, Wencker, Marion, Stockley, Robert A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2020
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301289/ https://www.ncbi.nlm.nih.gov/pubmed/32165400 http://dx.doi.org/10.1183/13993003.02410-2019

Ejemplares similares

Alpha-1 antitrypsin Pi*SZ genotype: estimated prevalence and number of SZ subjects worldwide
por: Blanco, Ignacio, et al.
Publicado: (2017)

Demographic and clinical characteristics of patients with α(1)-antitrypsin deficiency genotypes PI*ZZ and PI*SZ in the Spanish registry of EARCO
por: Torres-Durán, María, et al.
Publicado: (2022)

The effect of exacerbations on lung density in α(1)-antitrypsin deficiency
por: Strange, Charlie, et al.
Publicado: (2023)

Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme
por: Greulich, Timm, et al.
Publicado: (2018)

Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiency
por: Kim, Woo Jin, et al.
Publicado: (2012)

Diagnosing α(1)-antitrypsin deficiency: how to improve the current algorithm
por: McElvaney, Noel G.
Publicado: (2015)

Diagnosis and management of α(1)-antitrypsin deficiency in Europe: an expert survey
por: Horváth, Ildikó, et al.
Publicado: (2019)

Alpha-1 antitrypsin for cystic fibrosis complicated by severe cytokinemic COVID-19
por: McElvaney, Oliver J, et al.
Publicado: (2021)

The prevalence of liver abnormalities in individuals with ZZ Alpha-1 Antitrypsin deficiency
por: McElvaney, OF, et al.
Publicado: (2015)

Quantitative disease progression model of α‐1 proteinase inhibitor therapy on computed tomography lung density in patients with α‐1 antitrypsin deficiency
por: Tortorici, Michael A., et al.
Publicado: (2017)

Protocol for the EARCO Registry: a pan-European observational study in patients with α(1)-antitrypsin deficiency
por: Greulich, Timm, et al.
Publicado: (2020)

Pharmacokinetic comparability of Prolastin(®)-C to Prolastin(® )in alpha(1)-antitrypsin deficiency: a randomized study
por: Stocks, James M, et al.
Publicado: (2010)

Improving the Lives of Patients with Alpha-1 Antitrypsin Deficiency
por: Sandhaus, Robert A, et al.
Publicado: (2020)

Prevalence of α(1)-antitrypsin PiZZ genotypes in patients with COPD in Europe: a systematic review
por: Blanco, Ignacio, et al.
Publicado: (2020)

Impact of COVID-19 in Patients With Severe Alpha-1 Antitrypsin Deficiency: The IMCA1 Study of the EARCO Clinical Research Collaboration
por: Parr, David G., et al.
Publicado: (2022)

Is There a Therapeutic Role for Selenium in Alpha-1 Antitrypsin Deficiency?
por: Greene, Catherine M., et al.
Publicado: (2013)

Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach
por: Stockley, Robert A, et al.
Publicado: (2013)

Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency
por: Parr, David G, et al.
Publicado: (2009)

Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications
por: Chapman, Kenneth R, et al.
Publicado: (2018)

Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency
por: McLean, Caitriona, et al.
Publicado: (2009)

The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial
por: Campos, Michael A., et al.
Publicado: (2019)

Dysregulated neutrophil function in individuals with alpha-1 antitrypsin deficiency caused by modified membrane cholesterol content.
por: Jundi, Bakr, et al.
Publicado: (2015)

α(1)-Antitrypsin deficiency associated with increased risk of heart failure
por: Winther, Sine V., et al.
Publicado: (2023)

Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update
por: Blanco, Ignacio, et al.
Publicado: (2017)

Alpha-1 antitrypsin (AAT) augmentation therapy in individuals with the PI*MZ genotype: a pro/con debate on a working hypothesis
por: Barjaktarevic, Igor, et al.
Publicado: (2021)

Cystic fibrosis disease severity correlates with plasma levels of desmosine and isodesmosine, biomarkers of elastin degradation
por: Ma, Shuren, et al.
Publicado: (2019)

The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals
por: Dunlea, Danielle M, et al.
Publicado: (2018)

The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency
por: Schmid, ST, et al.
Publicado: (2012)

Risk factors for symptom onset in PI*Z alpha-1 antitrypsin deficiency
por: Mayer, Annyce S, et al.
Publicado: (2006)

Estimated Prevalence and Number of PiMZ Genotypes of Alpha-1 Antitrypsin in Seventy-Four Countries Worldwide
por: Martinez-González, Cristina, et al.
Publicado: (2021)

The prevalence of bronchiectasis in patients with alpha-1 antitrypsin deficiency: initial report of EARCO
por: Stockley, Robert A., et al.
Publicado: (2023)

COPD in individuals with the PiMZ alpha-1 antitrypsin genotype
por: Al Ashry, Haitham S., et al.
Publicado: (2017)

Alpha(1)-antitrypsin deficiency: current perspective on research, diagnosis, and management
por: Stolk, Jan, et al.
Publicado: (2006)

Alpha 1 Antitrypsin Therapy in Patients with Alpha 1 Antitrypsin Deficiency: Perspectives from a Registry Study and Practical Considerations for Self-Administration During the COVID-19 Pandemic
por: Herth, Felix J F, et al.
Publicado: (2021)

Imaging in alpha-1 antitrypsin deficiency: a window into the disease
por: Huang, Yuh-Chin Tony, et al.
Publicado: (2021)

Alpha-1 antitrypsin regulates neutrophil reactive oxygen species production via inhibition of key players of the respiratory burst oxidase system
por: Alfawaz, Bader, et al.
Publicado: (2013)

Alpha-1 proteinase inhibitors for the treatment of alpha-1 antitrypsin deficiency: safety, tolerability, and patient outcomes
por: Chotirmall, Sanjay H, et al.
Publicado: (2015)

Alpha-1 Antitrypsin Deficiency: The Learning Goes On
por: Stockley, Robert. A.
Publicado: (2020)

The significance of the F variant of alpha-1-antitrypsin and unique case report of a PiFF homozygote
por: Sinden, Nicola Jane, et al.
Publicado: (2014)

Interleukin-6: obstacles to targeting a complex cytokine in critical illness
por: McElvaney, Oliver J, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_igrs8si42jojkgshn2vgffq2gu